Tioga Pharmaceuticals Inc. raised $18 million in its second round of venture financing, money that will allow the San Diego biotech to complete a Phase III trial with asimadoline for diarrhea predominant irritable bowel syndrome (D-IBS). (BioWorld Today) Read More